Skip to main content
Erschienen in: Pediatric Surgery International 10/2021

26.07.2021 | Letter to the Editor

The impact of botulinum injection for hospitalized children with Hirschsprung-associated enterocolitis

verfasst von: Wendy Jo Svetanoff, Joseph Lopez, Pablo Aguayo, Richard J. Hendrickson, Tolulope A. Oyetunji, Rebecca M. Rentea

Erschienen in: Pediatric Surgery International | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Stasis from obstruction at the level of the internal anal sphincter (IAS) can lead to Hirschsprung-associated enterocolitis (HAEC) and may be improved by botulinum toxin (BT) injections. Our aim was to determine if BT injection during HAEC episodes decreased the number of recurrent HAEC episodes and/or increased the interval between readmissions.

Methods

A retrospective review was performed of patients admitted for HAEC from January 2010 to December 2019. Demographics and outcomes of patients who received BT were compared to patients who did not receive BT during their hospital stay.

Results

A total of 120 episodes of HAEC occurred in 40 patients; 30 patients (75%) were male, 7 (18%) had Trisomy 21 and 10 (25%) had long-segment disease. On multivariate analysis, patients who received BT during their inpatient HAEC episode had a longer median time between readmissions (p = 0.04) and trending toward an association with fewer readmissions prior to a follow-up clinic visit (p = 0.08).

Conclusion

The use of BT in HD patients hospitalized for HAEC is associated with an increased time between recurrent HAEC episodes and trended toward fewer recurrent episodes. The use of BT should be considered in the management of patients admitted with HAEC.
Literatur
1.
Zurück zum Zitat Levitt MA, Dickie B, Pena A (2010) Evaluation and treatment of the patients with Hirschsprung disease who is not doing well after a pull-through. Semin Pediatr Surg 19(2):146–153CrossRef Levitt MA, Dickie B, Pena A (2010) Evaluation and treatment of the patients with Hirschsprung disease who is not doing well after a pull-through. Semin Pediatr Surg 19(2):146–153CrossRef
3.
Zurück zum Zitat Langer JC, Rollins MD, Levitt M et al (2017) Guidelines for the management of postoperative obstructive symptoms in children with Hirschsprung disease. Pediatr Surg Int 33:523–526CrossRef Langer JC, Rollins MD, Levitt M et al (2017) Guidelines for the management of postoperative obstructive symptoms in children with Hirschsprung disease. Pediatr Surg Int 33:523–526CrossRef
4.
Zurück zum Zitat Han-Guerts IJM, Hendrix VC, de Blaauw I, Wijnen HWA, van Heurn ELW (2014) Outcome after anal intersphincteric botox injection in children with surgically treated Hirschsprung disease. JPGN 59(5):604–607 Han-Guerts IJM, Hendrix VC, de Blaauw I, Wijnen HWA, van Heurn ELW (2014) Outcome after anal intersphincteric botox injection in children with surgically treated Hirschsprung disease. JPGN 59(5):604–607
5.
Zurück zum Zitat Gosain A, Frykman PK, Cowles RA et al (2017) Guidelines for the diagnosis and management of Hirschsprung’s-associated Enterocolitis. Pediatr Surg Int 33(5):517–521CrossRef Gosain A, Frykman PK, Cowles RA et al (2017) Guidelines for the diagnosis and management of Hirschsprung’s-associated Enterocolitis. Pediatr Surg Int 33(5):517–521CrossRef
6.
Zurück zum Zitat Langer JC, Birnbaum E (1997) Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung’s disease. J Pediatr Surg 32(7):1059–1062CrossRef Langer JC, Birnbaum E (1997) Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung’s disease. J Pediatr Surg 32(7):1059–1062CrossRef
7.
Zurück zum Zitat Langer JC (2004) Persistent obstructive symptoms after surgery for Hirschsprung’s disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg 39:1458–1462CrossRef Langer JC (2004) Persistent obstructive symptoms after surgery for Hirschsprung’s disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg 39:1458–1462CrossRef
8.
Zurück zum Zitat Koivusalo AI, Pakarinen MP, Rintala RJ (2009) Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung’s disease. Pediatr Surg Int 25:873–876CrossRef Koivusalo AI, Pakarinen MP, Rintala RJ (2009) Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung’s disease. Pediatr Surg Int 25:873–876CrossRef
9.
Zurück zum Zitat Thakkar HS, Bassett C, Hsu A et al (2017) Functional outcomes in Hirschsprung’s disease: a single institution’s 12-year experience. J Pediatr Surg 52:277–280CrossRef Thakkar HS, Bassett C, Hsu A et al (2017) Functional outcomes in Hirschsprung’s disease: a single institution’s 12-year experience. J Pediatr Surg 52:277–280CrossRef
10.
Zurück zum Zitat Church JT, Gadepalli SK, Talishinsky T, Teielbaum DH, Jarboe MD (2017) Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung’s disease and internal anal sphincter achalasia. J Pediatr Surg 52:74–78CrossRef Church JT, Gadepalli SK, Talishinsky T, Teielbaum DH, Jarboe MD (2017) Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung’s disease and internal anal sphincter achalasia. J Pediatr Surg 52:74–78CrossRef
11.
Zurück zum Zitat Louis-Barrone C, Faure A et al (2019) Neurostimulation-guided anal intrasphincteric botulinum toxin injection in children with Hirschsprung disease. JPGN 68:527–532 Louis-Barrone C, Faure A et al (2019) Neurostimulation-guided anal intrasphincteric botulinum toxin injection in children with Hirschsprung disease. JPGN 68:527–532
12.
Zurück zum Zitat Roorda D, Abeln ZAM, Oosterlaan J, van Heurn LWE, Derikx JPM (2019) Botulinum toxin injections after surgery for Hirschsprung disease: systematic review and meta-analysis. World J Gastroenterol 25(25):3268–3280CrossRef Roorda D, Abeln ZAM, Oosterlaan J, van Heurn LWE, Derikx JPM (2019) Botulinum toxin injections after surgery for Hirschsprung disease: systematic review and meta-analysis. World J Gastroenterol 25(25):3268–3280CrossRef
13.
Zurück zum Zitat Nataraja RM, Ferguson P, King S, Lynch A, Pacilli M (2019) Management of Hirschsprung disease in Australia and New Zealand: a survey of the Australian and New Zealand Association of Paediatric Surgeons (ANZAPS). Pediatr Surg Int 35:419–423CrossRef Nataraja RM, Ferguson P, King S, Lynch A, Pacilli M (2019) Management of Hirschsprung disease in Australia and New Zealand: a survey of the Australian and New Zealand Association of Paediatric Surgeons (ANZAPS). Pediatr Surg Int 35:419–423CrossRef
14.
Zurück zum Zitat Patrus B, Nasr A, Langer JC, Gerstle JT (2011) Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease. J Pediatr Surg 46:184–187CrossRef Patrus B, Nasr A, Langer JC, Gerstle JT (2011) Intrasphincteric botulinum toxin decreases the rate of hospitalization for postoperative obstructive symptoms in children with Hirschsprung disease. J Pediatr Surg 46:184–187CrossRef
15.
Zurück zum Zitat Wester T, Granström AL (2015) Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease. Pediatr Surg Int 31:255–259CrossRef Wester T, Granström AL (2015) Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease. Pediatr Surg Int 31:255–259CrossRef
16.
Zurück zum Zitat Chumpitazi BP, Fishman SJ, Nurko S (2009) Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter. Am J Gastroenterol 104(4):976–983CrossRef Chumpitazi BP, Fishman SJ, Nurko S (2009) Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter. Am J Gastroenterol 104(4):976–983CrossRef
17.
Zurück zum Zitat Kastenberg ZJ, Wall N, Malhotra N et al (2020) The effect of multidisciplinary colorectal center development on short-term hospital readmissions for patients with anorectal malformations or Hirschsprung disease. J Pediatr Surg 55:541–544CrossRef Kastenberg ZJ, Wall N, Malhotra N et al (2020) The effect of multidisciplinary colorectal center development on short-term hospital readmissions for patients with anorectal malformations or Hirschsprung disease. J Pediatr Surg 55:541–544CrossRef
Metadaten
Titel
The impact of botulinum injection for hospitalized children with Hirschsprung-associated enterocolitis
verfasst von
Wendy Jo Svetanoff
Joseph Lopez
Pablo Aguayo
Richard J. Hendrickson
Tolulope A. Oyetunji
Rebecca M. Rentea
Publikationsdatum
26.07.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Surgery International / Ausgabe 10/2021
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI
https://doi.org/10.1007/s00383-021-04966-3

Weitere Artikel der Ausgabe 10/2021

Pediatric Surgery International 10/2021 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.